ArriVent BioPharma, Inc. AVBP Total debt
Total debt at other companies
Other financials
Where this comes from
Computed from long term debt + current portion long term debt + short term borrowings + operating lease liabilities + finance lease liabilities + financing obligations: $419K.
The official record: ArriVent BioPharma, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about ArriVent BioPharma, Inc.'s total debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ArriVent BioPharma, Inc.'s total debt?
- ArriVent BioPharma, Inc. (AVBP) reported total debt of $419K in Q1 2026.
- How has ArriVent BioPharma, Inc.'s total debt changed year-over-year?
- ArriVent BioPharma, Inc.'s total debt increased by 203.6% year-over-year, from $138K to $419K.
- What is the long-term trend for ArriVent BioPharma, Inc.'s total debt?
- Over 2 years (2023 to 2025), ArriVent BioPharma, Inc.'s total debt has grown at a -79.0% compound annual growth rate (CAGR), from $317K to $14K.
- What does total debt mean?
- Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.